Marks third Rare Pediatric Drug Designation granted by FDA for pipeline candidateHOUSTON--(BUSINESS WIRE)--IPS HEART, a privately held cell therapy company advancing its stem cell platform to develop new skeletal muscle and cardiac muscle generation treatments for Duchenne muscular dystrophy (a rare disease) and hea...